0000000000987270
AUTHOR
Leto G
showing 3 related works from this author
Acute myocardial effects of mitoxantrone in the rabbit
1987
Some clinical studies that were performed for the purpose of assessing the potential cardiotoxicity of mitoxantrone (DHAD) have shown that repeated administrations of the drugs in some patients cause a mild impairment of cardiac functions and morphological changes in the myocardial cells qualitatively similar to those elicited by anthracyclines. Since doxorubicin has been reported to cause acute cardiac effects, probably related to its chronic cardiotoxicity, experiments were carried out on the rabbit heart to investigate whether DHAD is also able to induce acute cardiac effects. Our results show that this drug caused a reversible dose-related impairment of cardiac contractility on the isol…
Characterization of the metastatic properties of two methylcholantrene-induced fibrosarcoma in mice
1988
MC1 and MC2 murine fibrosarcomas, following intramuscular innplantation in mice, release different numbers of tumor cells into the bloodstream and differ in their lung colonization potential following intravenous inoculation. Since these biological properties could be related to a different degree of maligancy, in vivo and in vitro experiments were performed vvith these two tunnors in an attempt to correlate their spontaneous metas-tatic potential with other parameters related to tunnor cell invasion and metastasis. Following intramuscular inplantation the MC2 fibrosarcoma was observed to have a slow but progressive ability to spontaneously metastasize while the MC1 lacked this capability. …
Liraglutide and Renal Outcomes in Type 2 Diabetes.
2017
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…